Management strategy for follicular lymphoma

DOI Web Site PubMed
  • FUKUHARA Noriko
    Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine

Bibliographic Information

Other Title
  • 濾胞性リンパ腫に対する治療戦略
  • ロホウセイ リンパシュ ニ タイスル チリョウ センリャク

Search this article

Description

<p>Follicular lymphoma (FL) is incurable with the current standard therapeutic strategy, although the natural history of FL has improved in the last few decades. Treatment strategy for FL is considered by stage and tumor burden. For advanced-stage FL patients with low tumor burden, monitoring remains an appropriate approach. Single agent rituximab is also suggested as a good alternative. The addition of rituximab to chemotherapy has improved overall survival in advanced-stage FL patients with high tumor burden. The optimal chemotherapy to partner with rituximab might be CHOP or bendamustine. Rituximab maintenance after successful induction rituximab-based chemotherapy prolongs PFS. Recently, progression within 24 months of first-line chemotherapy has been established as a predictor of inferior outcome, with a 50% risk of death in 5 years. Addressing this high-risk group is important for optimal future treatment strategies.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 58 (10), 2020-2025, 2017

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top